Nestle raises stake in food allergy drug developer Aimmune

(Reuters) - The health science unit of Nestle SA would pay $98 million (76 million pounds) to increase its stake in Aimmune Therapeutics Inc , the drug developer for food allergies said on Monday.The latest investment raises Nestle's ownership of Aimmune to about 19 percent. The companies also extended their two-year strategic collaboration to develop therapies for food allergy by another two years, Aimmune said.